Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

This study has been terminated.

(Low accrual)

Sponsor:

Information provided by (Responsible Party):

Masonic Cancer Center, University of Minnesota

ClinicalTrials.gov Identifier:

NCT00609739

First received: February 6, 2008

Last updated: January 31, 2012

Last verified: January 2012

History of Changes

Results First Received: November 22, 2011

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Leukemia
Interventions:	Drug: cyclosporine Drug: cytarabine Drug: filgrastim Drug: methotrexate Drug: methylprednisolone Drug: mitoxantrone hydrochloride Procedure: allogeneic bone marrow transplantation Procedure: umbilical cord blood transplantation Drug: Cis-Retinoic acid

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Cytarabine + Mitoxantrone	Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.

Participant Flow: Overall Study

	Cytarabine + Mitoxantrone
STARTED	1
COMPLETED	1
NOT COMPLETED	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Cytarabine + Mitoxantrone	Patients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.

Baseline Measures

	Cytarabine + Mitoxantrone
Number of Participants [units: participants]	1
Age [units: years]
<=18 years	1
Between 18 and 65 years	0
>=65 years	0
Gender [units: participants]
Female	1
Male	0
Region of Enrollment [units: participants]
United States	1

Outcome Measures

Show All Outcome Measures

1. Primary:

Disease-free Survival [ Time Frame: 1 year ]

Show Outcome Measure 1

2. Secondary:

Patients With Regimen-Related Toxicity [ Time Frame: Up to 30 Days Post Study Treatment ]

Show Outcome Measure 2

3. Secondary:

Patients With Graft-Versus-Host-Disease [ Time Frame: Up to 30 Days Post Study Treatment ]

Show Outcome Measure 3

4. Secondary:

Patients Who Relapsed [ Time Frame: 1 Year ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:

Name/Title: Margaret MacMillan, M.D.
Organization: Masonic Cancer Center, University of Minnesota
phone: 612-626-2778
e-mail: macmi002@umn.edu

No publications provided

Responsible Party:	Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:	NCT00609739 History of Changes
Other Study ID Numbers:	1999LS032, UMN-MT1999-08, 9906M07303
Study First Received:	February 6, 2008
Results First Received:	November 22, 2011
Last Updated:	January 31, 2012
Health Authority:	United States: Food and Drug Administration

To Top